Trial Profile
Phase II trial of CC 292 in patients with cancer.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2013
Price :
$35
*
At a glance
- Drugs Spebrutinib (Primary)
- Indications Cancer; Haematological malignancies; Lymphoma
- Focus Therapeutic Use
- 17 Jan 2013 New trial record